18334 U.S. PTO 031904

22390 U.S. PTO 10/804201 031904

Please type a plus sign (+) inside this box → [+]

PTO/SB/05 (08-03)
Approved for use through 7/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	C261 1080.1
First Inventor	NAIK, et al.
Title	Chrysogenazine Obtained from Fungus Penicillium Chrysogenum Having Antibacterial Activity
Express Mail Label No.	

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: **Mail Stop Patent Application**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. [] Fee Transmittal Form (e.g., PTO/SB/17) *(Submit an original, and a duplicate for fee processing)*
2. [X] Applicant claims small entity status. See 37 CFR 1.27.
3. [X] Specification [*Total Pages* 14]
 (preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross Reference to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to sequence listing, a table, or a computer program listing appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings *(if filed)*
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
4. [X] Drawing(s) *(35 U.S.C. 113)* [*Total Sheets* 6]
5. Oath or Declaration (unsigned) [X]
 a. [] Newly executed (original or copy)
 b. [] Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional with Box 18 completed)*
 i. [] DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. [X] Application Data Sheet. See 37 CFR 1.76 (2 pages)
7. [] CD-ROM or CD-R in duplicate, large table or Computer Program *(Appendix)*
8. Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all necessary)*
 a. [] Computer Readable Form (CRF)
 b. Specification Sequence Listing on:
 i. [] CD-ROM or CD-R (2 copies); or ii. [] paper
 c. [] Statements verifying identity of above copies

ACCOMPANYING APPLICATIONS PARTS

9. [] Assignment Papers (cover sheet & document(s))
10. [] 37 CFR 3.73(b) Statement *(when there is an assignee)* [] Power of Attorney
11. [] English Translation Document *(if applicable)*
12. [] Information Disclosure Statement (IDS)/PTO-1449 [] Copies of IDS Citations
13. [] Preliminary Amendment
14. [X] Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
15. [] Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. [] Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. [] Other:

18. If a CONTINUING APPLICATION, *check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:*

[] Continuation [] Divisional [] Continuation-in-part (CIP) of prior application No.: _____

Prior application information: Examiner _____ *Group / Art Unit:* _____

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

[X] *Customer Number or Bar Code Label* 26158 or [] *Correspondence address below*

Name	Nanda K. Alapati Womble, Carlyle, Sandridge & Rice				
Address	Post Office Box 7037				
City	Atlanta	*State*	GA	*Zip Code*	30357-0037
Country	United States	*Telephone*	703-394-2216	*Fax*	703-790-2623

Name (Print/Type)	Nanda K. Alapati	*Registration No. (Attorney/Agent)*	39,893
Signature	Nanda K. Alapati	*Date*	March 19, 2004